An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL

Chimeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory (r/r) B cell lymphomas but provides lasting remissions in only ∼40% of patients and is associated with serious adverse events. We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r) diffu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine 2024-02, Vol.5 (2), p.101421-101421, Article 101421
Hauptverfasser:	Prinz, Lars Fabian, Riet, Tobias, Neureuther, Daniel Felix, Lennartz, Simon, Chrobok, Danuta, Hübbe, Hanna, Uhl, Gregor, Riet, Nicole, Hofmann, Petra, Hösel, Marianna, Simon, Adrian Georg, Tetenborg, Luis, Segbers, Paul, Shimono, Joji, Gödel, Philipp, Balke-Want, Hyatt, Flümann, Ruth, Knittel, Gero, Reinhardt, Hans Christian, Scheid, Christoph, Büttner, Reinhard, Chapuy, Björn, Ullrich, Roland Tillmann, Hallek, Michael, Chmielewski, Markus Martin
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, CD19 - genetics B-Lymphocytes CAR T cells CD19 CD80 CD86 checkpoint ligand chimeric checkpoint receptor CTLA-4 Antigen DLBCL Humans Immunotherapy, Adoptive - methods lymphoma Lymphoma, Large B-Cell, Diffuse - etiology Lymphoma, Large B-Cell, Diffuse - therapy Mice neurotoxicity T-Lymphocytes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!